Topzle Topzle

Astrocytoma

Updated: Wikipedia source

Astrocytoma

Astrocytoma is a type of brain tumor. Astrocytomas (also astrocytomata) originate from a specific kind of star-shaped glial cell in the cerebrum called an astrocyte. This type of tumor does not usually spread outside the brain and spinal cord, and it does not usually affect other organs. After glioblastomas, astrocytomas are the second most common glioma and can occur in most parts of the brain and occasionally in the spinal cord. Within the astrocytomas, two broad classes are recognized in literature, those with:

Narrow zones of infiltration (mostly noninvasive tumors; e.g., pilocytic astrocytoma, subependymal giant cell astrocytoma, pleomorphic xanthoastrocytoma), that often are clearly outlined on diagnostic images Diffuse zones of infiltration (e.g., high-grade astrocytoma), that share various features, including the ability to arise at any location in the central nervous system, but with a preference for the cerebral hemispheres; they occur usually in adults, and have an intrinsic tendency to progress to more advanced grades. People can develop astrocytomas at any age. The low-grade type is more often found in children or young adults, while the high-grade type is more prevalent in adults. Astrocytomas in the base of the brain are more common in young people and account for roughly 75% of neuroepithelial tumors.

Infobox

Specialty
Neuro-oncology, neurosurgery

Tables

· Diagnosis › Grading
I
I
WHO grade
I
Astrocytomas
Pilocytic astrocytoma Subependymal giant cell astrocytoma Subependymoma
Description
Consist of slow-growing astrocytomas, benign, and associated with long-term survival. Individuals with very slow-growing tumors where complete surgical removal by stereotactic surgery is possible may experience total remission. Even if the surgeon is not able to remove the entire tumor, it may remain inactive or be successfully treated with radiation.
II
II
WHO grade
II
Astrocytomas
Low-grade (fibrillary) astrocytoma Pleomorphic xanthoastrocytoma Mixed oligoastrocytoma
Description
Consist of relatively slow-growing astrocytomas, usually considered benign that sometimes evolve into more malignant or as higher grade tumors. They are prevalent in younger people who often present with seizures. Median survival varies with the cell type of the tumor. Grade 2 astrocytomas are defined as being invasive gliomas, meaning that the tumor cells penetrate into the surrounding normal brain, making a surgical cure more difficult. People with oligodendrogliomas (which might share common cells of origin) have better prognoses than those with mixed oligoastrocytomas, who in turn have better prognoses than patients with (pure) low-grade astrocytomas. Other factors which influence survival include age (younger the better) and performance status (ability to perform tasks of daily living). Due to the infiltrative nature of these tumors, recurrences are relatively common. Depending on the patient, radiation or chemotherapy after surgery is an option. Individuals with grade 2 astrocytoma have a 5-year survival rate of about 34% without treatment and about 70% with radiation therapy. The median survival time is 4 years.
III
III
WHO grade
III
Astrocytomas
Anaplastic astrocytoma
Description
Consist of anaplastic astrocytomas. It is often related to seizures, neurologic deficits, headaches, or changes in mental status. The standard initial treatment is to remove as much of the tumor as possible without worsening neurologic deficits. Radiation therapy has been shown to prolong survival and is a standard component of treatment. Individuals with grade 3 astrocytoma have a median survival time of 18 months without treatment (radiation and chemotherapy). There is no proven benefit to adjuvant chemotherapy or supplementing other treatments for this kind of tumor. Although temozolomide is effective for treating recurrent anaplastic astrocytoma, its role as an adjuvant to radiation therapy has not been fully tested.
IV
IV
WHO grade
IV
Astrocytomas
Grade 4 Astrocytoma
Description
Consists of grade 4 astrocytoma (as of WHO 2021) that form following high-grade transformation of low-grade astrocytoma. These are more common in younger patients (mean age 45 versus 62 years). Surgical removal remains the mainstay of treatment, provided that unacceptable neurologic injury can be avoided. The extremely infiltrative nature of this tumor makes complete surgical removal impossible. Although radiotherapy rarely cures glioblastoma, studies show that it doubles the median survival of patients, compared to supportive care alone. The prognosis is worst for these grade 4 gliomas. Few patients survive beyond 3 years. Individuals with grade 4 astrocytoma have a median survival time of 17 weeks without treatment, 30 weeks with radiation, and 37 weeks with surgical removal of most of the tumor followed by radiation therapy. Long-term survival (at least five years) falls well under 3%.
WHO grade
Astrocytomas
Description
I
Pilocytic astrocytoma Subependymal giant cell astrocytoma Subependymoma
Consist of slow-growing astrocytomas, benign, and associated with long-term survival. Individuals with very slow-growing tumors where complete surgical removal by stereotactic surgery is possible may experience total remission. Even if the surgeon is not able to remove the entire tumor, it may remain inactive or be successfully treated with radiation.
II
Low-grade (fibrillary) astrocytoma Pleomorphic xanthoastrocytoma Mixed oligoastrocytoma
Consist of relatively slow-growing astrocytomas, usually considered benign that sometimes evolve into more malignant or as higher grade tumors. They are prevalent in younger people who often present with seizures. Median survival varies with the cell type of the tumor. Grade 2 astrocytomas are defined as being invasive gliomas, meaning that the tumor cells penetrate into the surrounding normal brain, making a surgical cure more difficult. People with oligodendrogliomas (which might share common cells of origin) have better prognoses than those with mixed oligoastrocytomas, who in turn have better prognoses than patients with (pure) low-grade astrocytomas. Other factors which influence survival include age (younger the better) and performance status (ability to perform tasks of daily living). Due to the infiltrative nature of these tumors, recurrences are relatively common. Depending on the patient, radiation or chemotherapy after surgery is an option. Individuals with grade 2 astrocytoma have a 5-year survival rate of about 34% without treatment and about 70% with radiation therapy. The median survival time is 4 years.
III
Anaplastic astrocytoma
Consist of anaplastic astrocytomas. It is often related to seizures, neurologic deficits, headaches, or changes in mental status. The standard initial treatment is to remove as much of the tumor as possible without worsening neurologic deficits. Radiation therapy has been shown to prolong survival and is a standard component of treatment. Individuals with grade 3 astrocytoma have a median survival time of 18 months without treatment (radiation and chemotherapy). There is no proven benefit to adjuvant chemotherapy or supplementing other treatments for this kind of tumor. Although temozolomide is effective for treating recurrent anaplastic astrocytoma, its role as an adjuvant to radiation therapy has not been fully tested.
IV
Grade 4 Astrocytoma
Consists of grade 4 astrocytoma (as of WHO 2021) that form following high-grade transformation of low-grade astrocytoma. These are more common in younger patients (mean age 45 versus 62 years). Surgical removal remains the mainstay of treatment, provided that unacceptable neurologic injury can be avoided. The extremely infiltrative nature of this tumor makes complete surgical removal impossible. Although radiotherapy rarely cures glioblastoma, studies show that it doubles the median survival of patients, compared to supportive care alone. The prognosis is worst for these grade 4 gliomas. Few patients survive beyond 3 years. Individuals with grade 4 astrocytoma have a median survival time of 17 weeks without treatment, 30 weeks with radiation, and 37 weeks with surgical removal of most of the tumor followed by radiation therapy. Long-term survival (at least five years) falls well under 3%.

References

  1. WebMD
    https://www.webmd.com/cancer/brain-cancer/what-is-astrocytoma
  2. Astrocytoma at eMedicine
    https://emedicine.medscape.com/article/283453-overview
  3. The Lecturio Medical Concept Library
    https://www.lecturio.com/concepts/astrocytoma/
  4. PLOS ONE
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264559
  5. APL Bioengineering
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229984
  6. emedicine.medscape.com
    https://emedicine.medscape.com/article/283453-workup#c6
  7. mdguidelines.com Astrocytoma Archived 2017-11-30 at the Wayback Machine Retrieved on Mars 26, 2010
    http://www.mdguidelines.com/astrocytoma
  8. Cancer Science
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11159448
  9. Mayo Clinic
    https://www.mayoclinic.org/diseases-conditions/glioma/symptoms-causes/syc-20350251
  10. Mayo Clinic Proceedings
    https://doi.org/10.4065%2F82.10.1271
  11. CBTRUS
    http://www.cbtrus.org/
  12. Nat Rev Clin Oncol
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904519
  13. Brady, John (December 1, 1996). "I'm Still Lee Atwater", The Washington Post, retrieved 2010-04-11.
    https://www.washingtonpost.com/wp-srv/style/longterm/books/bckgrnd/atwater.htm
  14. Waring, Thomas R., ed. "Jury Blames Tumor For Killings: Doctor Says Whitman Unaffected"" The News and Courier [Charlesto
  15. Henderson, Heather (1999). "Dan Quisenberry - In His Own Words" The 1999 Big Bad Baseball Annual. Retrieved June 24, 201
  16. "Deaths England and Wales 1984–2006"
    https://web.archive.org/web/20090831050858/http://www.findmypast.com/BirthsMarriagesDeaths.jsp
  17. "Former world champion Burns dies"
    http://news.bbc.co.uk/sport1/hi/motorsport/world_rally/4472642.stm
  18. PWI Presents: 2007 Wrestling Almanac and book of facts
  19. "Matt Cappotelli to undergo brain surgery"
    http://www.wwe.com/inside/news/archive/cappotelliupdate
  20. "Cappotelli undergoes surgery"
    http://www.wwe.com/inside/news/archive/cappotellisurgery
  21. "Cappotelli recovering well"
    http://www.wwe.com/inside/news/archive/cappotelliupdate
  22. The Courier-Journal
    http://www.courier-journal.com/article/20131112/BUSINESS/311120027/Helping-wrestlers-get-grip
  23. Ohio Valley Wrestling
    https://web.archive.org/web/20150820044520/http://www.ovwrestling.com/training/beginner
  24. TheWrap
    https://www.thewrap.com/matt-cappotelli-former-wwe-wrestler-tough-enough-winner-dies-38/
  25. USA Today
    https://www.usatoday.com/story/entertainment/celebrities/2025/08/05/kelley-mack-dead-at-33-the-walking-dead/85533520007/
  26. Cite error: The named reference Moses was invoked but never defined (see the help page).
  27. Screen Rant
    https://screenrant.com/kelley-mack-death-obituary/
  28. People
    https://people.com/the-walking-dead-actress-kelley-mack-dies-at-33-11785594
  29. Variety
    https://variety.com/2025/tv/news/kelley-mack-dead-9-1-1-the-walking-dead-1236479304/
  30. TVLine
    https://tvline.com/news/kelley-mack-dead-the-walking-dead-addy-cause-of-death-1235485777/
Image
Source:
Tip: Wheel or +/− to zoom, drag to pan, Esc to close.